No Data
No Data
Gene Therapy Developers Rise on Comments From FDA's Makary
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 29% Dive
REGENXBIO Is Maintained at Neutral by Goldman Sachs
Goldman Sachs Maintains Regenxbio(RGNX.US) With Hold Rating, Cuts Target Price to $12
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $25
RBC Cuts Price Target on REGENXBIO to $25 From $30, Keeps Outperform, Speculative Risk